Erasca Inc (ERAS) shares surged by 16.18% to reach a 52-week high of $5.17, driven by positive market dynamics and strong investor interest.
This increase is attributed to Erasca Inc surpassing the average analyst 12-month target price of $4.12, which has prompted a reassessment of investment strategies among investors. Analysts have upgraded Erasca to an overweight rating, reflecting optimism about its future performance and potentially attracting more institutional interest. The stock's rise indicates a shift in market sentiment, as investors are encouraged by the company's improving fundamentals and the potential for further price increases.
The implications of this price movement suggest that Erasca Inc is gaining traction in the market, with analysts' upgrades likely to enhance investor confidence and drive further interest in the biopharmaceutical sector.
Wall Street analysts forecast ERAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ERAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 6.760
Low
1.00
Averages
4.50
High
6.00
Current: 6.760
Low
1.00
Averages
4.50
High
6.00
Morgan Stanley
Equal Weight
maintain
$2 -> $4
2026-01-08
New
Reason
Morgan Stanley
Price Target
$2 -> $4
2026-01-08
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Erasca to $4 from $2 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Piper Sandler
Overweight
initiated
$5
2026-01-07
Reason
Piper Sandler
Price Target
$5
2026-01-07
initiated
Overweight
Reason
Piper Sandler initiated coverage of Erasca with an Overweight rating and $5 price target. The company is is advancing a "potentially differentiated" RAS-targeted pipeline including a pan-RAS molecular glue, and a pan- KRAS inhibitor, the analyst tells investors in a research note. The firm says preclinical data suggests the potential for superior RAS inhibition and anti-tumor activity virus Revolution Medicines' daraxonrasib.
BofA
Underperform
maintain
$1 -> $2
2026-01-06
Reason
BofA
Price Target
$1 -> $2
2026-01-06
maintain
Underperform
Reason
BofA raised the firm's price target on Erasca to $2 from $1 and keeps an Underperform rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.
Mizuho
Outperform
upgrade
$4 -> $5
2025-12-09
Reason
Mizuho
Price Target
$4 -> $5
2025-12-09
upgrade
Outperform
Reason
Mizuho raised the firm's price target on Erasca to $5 from $4 and keeps an Outperform rating on the shares. The firm is "increasingly encouraged and constructive" on the RAS space and is bullish on Erasca ahead of its first U.S. Phase 1 clinical data for its two lead assets, ERAS-0015 and ERAS-4001. Mizuho sees large addressable markets for both candidates and notes that data is expected in 2026. The analyst sees an attractive risk/reward at current share levels.
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
